Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply ...
Within molecular biology, few regulatory proteins have attracted as much sustained attention as P21, a cyclin-dependent ...
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From ...
Asieris Pharmaceuticals Co. Ltd. has identified compounds acting as inhibitors of CDK1/cyclin A2, CDK2/cyclin E1, CDK4/cyclin D1 and CDK6/cyclin D1 reported to be useful for the treatment of breast ...
Pfizer announces positive topline phase 2 results for next-generation CDK4 inhibitor, atirmociclib, in second-line metastatic breast cancer: New York Wednesday, March 18, 2026, 09 ...
Pfizer on Tuesday said the randomized Phase 2 study met its primary endpoint, showing a 40% reduction in the risk of disease progression or death with a manageable safety profile.
New research offers unprecedented insight into how an enigmatic enzyme, known as CDK7, drives the cell cycle and cell proliferation. For organs to develop, grow and regenerate, cells must proliferate.
In progressive fibrotic diseases, which can occur in nearly all organs, myofibroblasts are activated to differentiate into proliferating fibroblastic cells that express genes that lead to deposition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results